FAM19A4 and hsa-miR124-2 Double Methylation as Screening for ASC-H- and CIN1 HPV-Positive Women
Pathogens · 11.04.2024 · 13 (4) · 312
DOI: 10.3390/pathogens13040312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, online erschienen am 11.04.2024. Verfasst von Cinzia Peronace und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Microbiology and Virology, PO Pugliese, AOU Renato Dulbecco, 88100 Catanzaro, Italy. Hauptthemen laut MEDLINE: MicroRNAs, DNA Methylation, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The DNA methylation levels of host cell genes increase with the severity of the cervical intraepithelial neoplasia (CIN) grade and are very high in cervical cancer. Our study aims to evaluate FAM19A4 and hsa-miR124-2 methylation in Atypical Squamous cells with high-grade squamous intraepithelial lesions (ASC-H) and in CIN1, defined as low-grade squamous intraepithelial lesions (LSILs) by the Bethesda classification, as possible early warning biomarkers for managing women with high-risk HPV infections (hrHPV). FAM19A4 and hsa-miR124-2 methylation tests were conducted on fifty-six cervical screening samples from a subset of women aged 30–64 years old. Specimens were collected into ThinPrep PreservCyt Solution. Their HrHPV genotype and cytology diagnosis were known. A Qiasure (Qiagen) was used for FAM19A4 and hsa-miR124-2 methylation testing on bisulfite-converted DNA, according to the manufacturer’s specifications. The reported results were hypermethylation-positive or -negative. We found that FAM194A4 and hsa-miR124-2 methylation was detected in 75% of ASC-H cases with a persistent infection of hrHPV. A total of 60% of CIN1 lesions were found to be positive for methylation, and 83.3% were when the cytology was CIN2/3. In addition, as a novelty of this pilot study, we found that combined FAM19A4 and hsa-miR124-2 methylation positivity rates (both methylated) were associated with the HPV genotypes 16, 18, and 59 and covered 22 and 25% of ASC-H and CIN1 cases, respectively. The methylation of these two genes, in combination with HPV genotyping, can be used as an early warning biomarker in the management and follow-up of women with ASC-H and CIN1 to avoid their progression to cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Microbiology and Virology, PO Pugliese, AOU Renato Dulbecco, 88100 Catanzaro, Italy.
- Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende (CS), Italy.
- Galascreen Laboratories, University of Calabria, 87036 Rende (CS), Italy.
- Department of Health Sciences, University of Magna Graecia, 88100 Catanzaro, Italy.
ORCID-Profile: Erika Cione, Diana Marisol Abrego-Guandique, Roberto Cannataro, Pasquale Minchella
Zitieren
APA
Peronace, C., Cione, E., Abrego-Guandique, D. M., Fazio, M., Panduri, G., Caroleo, M. C., Cannataro, R., & Minchella, P. (2024). FAM19A4 and hsa-miR124-2 Double Methylation as Screening for ASC-H- and CIN1 HPV-Positive Women. Pathogens, 13(4), 312. https://doi.org/10.3390/pathogens13040312
Vancouver
Peronace C, Cione E, Abrego-Guandique DM, Fazio M, Panduri G, Caroleo MC, et al. FAM19A4 and hsa-miR124-2 Double Methylation as Screening for ASC-H- and CIN1 HPV-Positive Women. Pathogens. 2024;13(4):312. doi:10.3390/pathogens13040312
BibTeX
@article{Peronace2024,
author = {Peronace, Cinzia and Cione, Erika and Abrego-Guandique, Diana Marisol and Fazio, Marco De and Panduri, Giuseppina and Caroleo, Maria Cristina and Cannataro, Roberto and Minchella, Pasquale},
title = {FAM19A4 and hsa-miR124-2 Double Methylation as Screening for ASC-H- and CIN1 HPV-Positive Women},
journal = {Pathogens},
year = {2024},
volume = {13},
number = {4},
pages = {312},
doi = {10.3390/pathogens13040312}
}
EUVIMED